[go: up one dir, main page]

DK3368071T3 - Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning - Google Patents

Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning Download PDF

Info

Publication number
DK3368071T3
DK3368071T3 DK16860952.7T DK16860952T DK3368071T3 DK 3368071 T3 DK3368071 T3 DK 3368071T3 DK 16860952 T DK16860952 T DK 16860952T DK 3368071 T3 DK3368071 T3 DK 3368071T3
Authority
DK
Denmark
Prior art keywords
methods
long
botulinum toxin
cosmetic effect
term therapeutic
Prior art date
Application number
DK16860952.7T
Other languages
English (en)
Inventor
Curtis L Ruegg
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58630886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3368071(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Application granted granted Critical
Publication of DK3368071T3 publication Critical patent/DK3368071T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DK16860952.7T 2015-10-29 2016-10-28 Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning DK3368071T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248255P 2015-10-29 2015-10-29
PCT/US2016/059492 WO2017075468A1 (en) 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Publications (1)

Publication Number Publication Date
DK3368071T3 true DK3368071T3 (da) 2022-05-02

Family

ID=58630886

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16860952.7T DK3368071T3 (da) 2015-10-29 2016-10-28 Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning

Country Status (16)

Country Link
US (2) US20180311333A1 (da)
EP (1) EP3368071B1 (da)
JP (2) JP6955491B2 (da)
KR (1) KR102794108B1 (da)
CN (1) CN109069608A (da)
AU (2) AU2016343748A1 (da)
BR (1) BR112018008684A2 (da)
CA (1) CA3003447A1 (da)
CO (1) CO2018005361A2 (da)
DK (1) DK3368071T3 (da)
ES (1) ES2907652T3 (da)
IL (2) IL259016A (da)
MX (1) MX2018005256A (da)
RU (1) RU2018119765A (da)
SG (2) SG10202004337WA (da)
WO (1) WO2017075468A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608249A2 (pt) * 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
CA2766521C (en) * 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
JP5951490B2 (ja) * 2009-10-21 2016-07-13 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
SG10202004337WA (en) 2015-10-29 2020-06-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
RU2766147C2 (ru) * 2017-03-22 2022-02-08 Бонти, Инк. Применение ботулинических нейротоксинов в лечении
WO2018213710A1 (en) * 2017-05-18 2018-11-22 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
EP3641746B1 (en) 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
EP3703738A4 (en) * 2017-11-03 2021-09-08 ReVance Therapeutics, Inc. BOTULINIC TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTARY FASCIITIS, WITH EXTENDED DURATION OF EFFECT
MX2020005785A (es) * 2017-12-04 2020-10-28 Revance Therapeutics Inc Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto.
CN112955166A (zh) * 2018-09-13 2021-06-11 阿勒根公司 治疗咬肌肥大的方法
JP2022533113A (ja) * 2019-05-14 2022-07-21 エイリオン セラピューティクス， インコーポレイテッド ピーク効果の遅延および／または応答持続時間の延長
AU2021240083A1 (en) * 2020-03-18 2022-10-20 Revance Therapeutics, Inc. Injectable botulinum toxin methods for treating headaches
KR102397708B1 (ko) * 2020-04-29 2022-05-16 한국화학연구원 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
KR20230086752A (ko) * 2020-10-13 2023-06-15 레반스 테라퓨틱스, 아이엔씨. 경부 근긴장이상증의 치료 방법
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
CN117693366A (zh) * 2021-02-21 2024-03-12 雷文斯治疗公司 用于治疗上肢痉挛的方法和组合物
WO2022228443A1 (en) * 2021-04-26 2022-11-03 Shanghaitech University Intramuscular compositions of botulinum neurotoxins
WO2023085849A1 (ko) * 2021-11-15 2023-05-19 (주)메디톡스 보툴리눔 독소 조성물
WO2023239229A1 (ko) * 2022-06-10 2023-12-14 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드
KR102714765B1 (ko) * 2023-05-04 2024-10-11 주식회사 파마리서치바이오 Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제
WO2025064729A1 (en) * 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
CA2494241C (en) 2000-02-08 2011-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
HRP20180739T1 (hr) 2008-12-31 2018-06-29 Revance Therapeutics, Inc. Injekcijske formulacije botulinskog toksina
CA2766521C (en) * 2009-06-25 2020-07-21 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
HRP20171483T1 (hr) * 2011-01-07 2017-12-01 Revance Therapeutics, Inc. Topikalni pripravak koji se sastoji od botulinskog toksina i boje
MX2014011376A (es) 2012-03-22 2014-10-14 Revance Therapeutics Inc Metodo de tratamiento de arrugas mediante agentes quimiodenervantes topicos.
MX370929B (es) * 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
SG10202004337WA (en) 2015-10-29 2020-06-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
RU2018119765A3 (da) 2020-03-17
US20180311333A1 (en) 2018-11-01
AU2016343748A1 (en) 2018-05-17
JP2022008814A (ja) 2022-01-14
KR20180077202A (ko) 2018-07-06
CN109069608A (zh) 2018-12-21
WO2017075468A1 (en) 2017-05-04
CO2018005361A2 (es) 2018-10-10
KR102794108B1 (ko) 2025-04-11
NZ742018A (en) 2024-07-05
CA3003447A1 (en) 2017-05-04
SG11201803566TA (en) 2018-05-30
RU2018119765A (ru) 2019-12-02
AU2023241373A1 (en) 2023-10-26
MX2018005256A (es) 2019-09-04
ES2907652T3 (es) 2022-04-25
JP6955491B2 (ja) 2021-10-27
IL286472A (en) 2021-10-31
SG10202004337WA (en) 2020-06-29
US20220062400A1 (en) 2022-03-03
EP3368071A1 (en) 2018-09-05
BR112018008684A2 (pt) 2018-11-27
EP3368071A4 (en) 2019-05-29
EP3368071B1 (en) 2022-01-26
JP2018531984A (ja) 2018-11-01
IL259016A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
DK3368071T3 (da) Injicerbare botulinumtoksinformuleringer og fremgangsmåder til anvendelse deraf med langvarig terapeutisk eller kosmetisk virkning
DK3386484T3 (da) Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3294770T4 (da) Terapeutiske og diagnostiske fremgangsmåder til cancer
DK3142637T3 (da) Keratin treatment formulations and methods
DK3250237T3 (da) Hemiasterlinderivater til konjugering og terapi
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
PL3145522T3 (pl) Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
IL275032A (en) Injectable botulinum toxin formulations and methods of using them with a high response rate and long duration of effect
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf
DK3302630T3 (da) Sprøjtestøtte og autoinjektor
GB201519200D0 (en) Skin care composition and method thereof
DK3275454T3 (da) Farmaceutisk sammensætning med silybin, ve og l-carnitin
DK3328368T3 (da) Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem
EP3600221A4 (en) BOTULINARY NEUROTOXINS FOR USE IN THERAPY
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3324938T3 (da) Topikale formuleringer og behandlinger
PL3367995T3 (pl) Kompozycja do pielęgnacji skóry oraz jej sposób
FR3020946B1 (fr) Nouvelles preparations cosmetiques et/ou dermatologiques extemporanees